Bayer has agreed to pay up to $7.25 billion to settle lawsuits from people who claim the weed killer Roundup caused their cancer. On Friday, a judge in Missouri gave final approval to the nationwide agreement, which will distribute funds to thousands of individuals diagnosed with non-Hodgkin lymphoma.
The settlement resolves a major portion of the legal battles surrounding glyphosate, the active ingredient in Roundup. Under the terms of the agreement in circuit court, affected individuals could receive compensation ranging from $10,000 to $165,000. The specific amount depends on several factors, including the age at diagnosis and the level of occupational exposure to the herbicide.
Massive Payout for Cancer Victims
Timothy Boyer, the presiding judge, described the agreement as one of the largest in the history of mass tort personal-injury class action settlements. The funds will go to people who have been or will be diagnosed with non-Hodgkin lymphoma, a type of blood cancer. Plaintiffs have long argued that their exposure to glyphosate directly contributed to their illness.
Christopher Seeger, an attorney representing the plaintiffs, stated that the final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice. The legal battle has spanned years, with thousands of cases moving through state and federal courts across the United States.
Legal and Political Context
This settlement comes on top of a previous agreement where Bayer paid between $10 billion and $11 billion to resolve more than 100,000 claims. Earlier this year, the U.S. Supreme Court ruled in favor of the German company, determining that it could be shielded from certain state court lawsuits regarding warnings about cancer risks.
Bayer CEO Bill Anderson called the settlement a decisive milestone that will mitigate the risks of pending and future litigation. The company has consistently denied that its product causes cancer, despite scientific debates over the years. The World Health Organization’s cancer agency concluded years ago that glyphosate is probably carcinogenic to humans, a finding echoed by prominent environmental health scientists recently.
While the Environmental Protection Agency stated it did not identify risks of concern from glyphosate uses, the agency is currently reviewing the evidence following pressure from advocates. The issue has also entered the political sphere, with concerns about glyphosate safety influencing policy discussions. However, the Trump administration has taken steps to support the herbicide industry, including siding with Bayer in the Supreme Court case and issuing an executive order to promote domestic production.
Bayer removed glyphosate from its U.S. products used in residential settings several years ago, though the chemical remains in use within the agricultural industry. The new settlement marks a significant financial and legal resolution for the agrochemical giant as it moves forward from the decade-long controversy.
Source: NPR

